Ireland
--:--IST
Starting soon Not applicable

Evaluation of Differences Between the Standered NAC Regimen Protocol and the SNAP Regimen Protocol in the Treatment of Paracetamol Toxicity for Cases Presented Early and Late to Assiut University Hospitals in Terms of Safety and Efficiecy.

NCT07454590 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-04-01
Last updated
2026-03-06

Condition(s) studied

Paracetamol Toxicity

Investigational drug(s) / intervention(s)

Evidence-based medical care for paracetamol toxicityEvidence-based medical care for paracetamol toxicityEvidence-based medical care for paracetamol toxicityEvidence-based medical care for paracetamol toxicity

Evidence-based medical care for paracetamol toxicity: adminstration of Standered 21 h NAC regimen for patient comes early within 8 h from ingestion of toxic dose of paracetamol

Evidence-based medical care for paracetamol toxicity: adminstration of Standered 21 h NAC regimen for patient comes late after 8 h from ingestion of toxic dose of paracetamol

Evidence-based medical care for paracetamol toxicity: adminstration of 12 h NAC regimen for patient comes early within 8 h from ingestion of toxic dose of paracetamol

Evidence-based medical care for paracetamol toxicity: adminstration of 12 h NAC regimen for patient comes late after 8 h from ingestion of toxic dose of paracetamol

Study summary

Evaluation of differences between the 21 h NAC regimen protocol and the 12 h NAC regimen protocol in the treatment of paracetamol toxicity (over dose) for cases presented early and late to Assiut University Hospitals in terms of safety and efficiecy.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * All cases admitted to Assiut University Hospitals with history of acute paracetamol overdose ingestion . Exclusion Criteria: * \* Co-ingestion of other hepatotoxic drugs . * Pre-existing liver diseases: Chronic hepatitis B or C, Autoimmune hepatitis, Wilson's disease, Known cirrhosis , Sepsis, shock, or hypoxic injury affecting the liver. * Hemolytic disorders causing abnormal LFTs. * Genetic or metabolic diseases that affect liver functions.

Primary outcome measure(s)

  • 1-Change in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) — 1- Day 2
    1-Mean change in ALT and AST levels (IU/L) from baseline to end of treatment
  • change in serum creatinine level — Day 2
    Mean change in serum creatinine (mg/dL) from baseline to end of treatment.
  • Incidence of adverse drug reactions — Day 2
    Number of participants who develop adverse drug reactions including nausea, vomiting, or anaphylactoid reactions during treatment

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine Assiut University Asyut Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07454590 on ClinicalTrials.gov ↗ ← All trials in Egypt